
Avinger (AVGR) Stock Forecast & Price Target
Avinger (AVGR) Analyst Ratings
Bulls say
Avinger Inc. is poised for significant revenue growth due to its planned expansion of the sales and clinical support team by over 25% in the fourth quarter, with expectations for further increase in the coming year. Successful commercialization of new products and anticipated FDA registration are expected to enhance gross margins starting in late 2025 or early 2026, particularly through collaboration with Zylox-Tonbridge. The combination of these factors, alongside strong market adoption of the Tigereye ST device, positions Avinger favorably for meaningful revenue growth in the short to mid-term.
Bears say
Avinger Inc has faced challenges in revenue growth, primarily due to underperformance in product sales within its core market of peripheral artery disease, where the majority of its income is generated. Additionally, the company has encountered increased operational costs and inefficiencies, which have negatively impacted its profitability and financial stability. Furthermore, the competitive landscape within the medical device industry, coupled with regulatory hurdles, presents ongoing risks that could hinder future performance and market expansion.
This aggregate rating is based on analysts' research of Avinger and is not a guaranteed prediction by Public.com or investment advice.
Avinger (AVGR) Analyst Forecast & Price Prediction
Start investing in Avinger (AVGR)
Order type
Buy in
Order amount
Est. shares
0 shares